HALO
Halozyme Therapeutics, Inc. · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2026
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | 0 | 502.79K | $49.11M | n/a | n/a |
| Q2 2026 | 133 | -1 | 91.19M | $6.60B | +6 | −6 |
| Q1 2026 | 136 | +1 | 88.77M | $5.36B | +7 | −7 |
| Q4 2025 | 135 | -1 | 97.38M | $6.16B | +1 | −1 |
| Q3 2025 | 22 | +1 | 49.86M | $3.66B | +1 | −1 |
| Q2 2025 | 19 | 0 | 43.24M | $2.25B | n/a | n/a |
| Q1 2025 | 16 | -1 | 15.61M | $996.39M | n/a | −1 |
| Q4 2024 | 17 | +3 | 17.59M | $840.95M | +4 | −1 |
| Q3 2024 | 13 | -1 | 6.97M | $398.81M | n/a | −1 |
| Q2 2024 | 14 | n/a | 8.14M | $426.06M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Assenagon Asset Management S.A. | 396.87K | -80.1% | $43.81M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 2 | Wealth Enhancement Advisory… | 105.85K | +49.5% | $5.29M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 3 | TD Waterhouse Canada Inc. | 71 | -38.8% | $7,593 | 0.0% | ▼ Trim | 3 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 630 holders, 119.44M shares, $7.40B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director · 200 sh · $22,102
Officer, Director · 11.90K sh · $1.31M
Officer, Director · 3.09K sh · $336,526
Officer, Director · 4.81K sh · $520,341
Officer, Director · 8.60K sh · $954,867
Officer, Director · 200 sh · $22,739
Officer, Director · 900 sh · $101,502
Officer, Director · 10.30K sh · $1.15M
Officer, Director · 1.78K sh · $197,245
Officer, Director · 9.92K sh · $1.09M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology